---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-266860"
form_type: "8-K"
ticker: "ACET"
cik: "0001720580"
company_name: "Adicet Bio, Inc."
filed_at: "2025-11-05T23:59:59+00:00"
generated_at: "2026-05-17T00:20:20.173202+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Adicet Bio Q3 net loss $26.9M; positive ADI-001 Phase 1 data in LN/SLE; cash runway extended to H2 2027

## Summary
- Positive Phase 1 ADI-001 data in 7 LN/SLE patients: SLEDAI-2K reductions, improved renal function, no Grade 2+ CRS or ICANS.
- Plans FDA meeting Q1 2026 for potentially pivotal trial; initiation targeted Q2 2026.
- Q3 2025 net loss $26.9M ($0.29 loss per share); R&D $22.9M, G&A $5.1M; cash $103.1M as of Sep 30.
- Raised $74.8M net proceeds in October 2025 registered direct offering; cash runway into H2 2027.
- ADI-212 regulatory filing for mCRPC on track Q1 2026; initial data expected H2 2026.

## SEC filing metadata
- accession: 0001193125-25-266860
- form_type: 8-K
- ticker: ACET
- cik: 0001720580
- company_name: Adicet Bio, Inc.
- filed_at: 2025-11-05T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/0001193125-25-266860-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1720580/000119312525266860/acet-20251105.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-266860
- JSON: https://secwatch.observer/filing/0001193125-25-266860.json
- Plain text: https://secwatch.observer/filing/0001193125-25-266860.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.